109 related articles for article (PubMed ID: 3435990)
21. Pluronic F-127 gels as a novel vehicle for rectal administration of indomethacin.
Miyazaki S; Yokouchi C; Nakamura T; Hashiguchi N; Hou WM; Takada M
Chem Pharm Bull (Tokyo); 1986 Apr; 34(4):1801-8. PubMed ID: 3719880
[No Abstract] [Full Text] [Related]
22. [Effects of in vitro conditions on release behavior of different types of sustained and controlled release formulations of breviscapin].
He Y; Zeng XT; Pan WS
Yao Xue Xue Bao; 2008 Nov; 43(11):1161-4. PubMed ID: 19239039
[TBL] [Abstract][Full Text] [Related]
23. Thermally reversible xyloglucan gels as vehicles for rectal drug delivery.
Miyazaki S; Suisha F; Kawasaki N; Shirakawa M; Yamatoya K; Attwood D
J Control Release; 1998 Dec; 56(1-3):75-83. PubMed ID: 9801431
[TBL] [Abstract][Full Text] [Related]
24. Development and evaluation of matrix and two layered sustained release suppositories of theophylline.
Maity S; Sa B; Bandyopadhyay AK
Boll Chim Farm; 2001; 140(6):462-6. PubMed ID: 11822240
[TBL] [Abstract][Full Text] [Related]
25. Matrix polymeric excipients: comparing a novel interpolyelectrolyte complex with hydroxypropylmethylcellulose.
Lu Z; Chen W; Olivier E; Hamman JH
Drug Deliv; 2008 Feb; 15(2):87-96. PubMed ID: 18293194
[TBL] [Abstract][Full Text] [Related]
26. Controlled systemic delivery of indomethacin using membrane-moderated, cream formulation-based transdermal devices.
Rao PR; Chalasani KB; Chauhan AS; Jain AK; Diwan PV; Ram MK
Drug Deliv; 2006; 13(3):207-13. PubMed ID: 16556573
[TBL] [Abstract][Full Text] [Related]
27. In vivo and in vitro release of indomethacin from water-soluble and fatty base suppositories.
Furuno K; Gomita Y; Yoshida T; Oishi R; Saeki K; Araki Y
Acta Med Okayama; 1992 Aug; 46(4):223-31. PubMed ID: 1442146
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of polyvinyl alcohol hydrogel as a sustained-release vehicle for rectal administration of indomethacin.
Morimoto K; Nagayasu A; Fukanoki S; Morisaka K; Hyon SH; Ikada Y
Pharm Res; 1989 Apr; 6(4):338-41. PubMed ID: 2748522
[TBL] [Abstract][Full Text] [Related]
29. Developing dissolution testing methodologies for extended-release oral dosage forms with supersaturating properties. Case example: Solid dispersion matrix of indomethacin.
Tajiri T; Morita S; Sakamoto R; Mimura H; Ozaki Y; Reppas C; Kitamura S
Int J Pharm; 2015 Jul; 490(1-2):368-74. PubMed ID: 26022889
[TBL] [Abstract][Full Text] [Related]
30. 3D Printed "Starmix" Drug Loaded Dosage Forms for Paediatric Applications.
Scoutaris N; Ross SA; Douroumis D
Pharm Res; 2018 Jan; 35(2):34. PubMed ID: 29368113
[TBL] [Abstract][Full Text] [Related]
31. Sustained-release and intragastric-floating granules of indomethacin using chitosan in rabbits.
Miyazaki S; Yamaguchi H; Yokouchi C; Takada M; Hou WM
Chem Pharm Bull (Tokyo); 1988 Oct; 36(10):4033-8. PubMed ID: 3245982
[No Abstract] [Full Text] [Related]
32. In vitro drug liberation and kinetics of sustained release indomethacin suppository.
Uzunkaya G; Bergişadi N
Farmaco; 2003 Jul; 58(7):509-12. PubMed ID: 12818689
[TBL] [Abstract][Full Text] [Related]
33. [Preparation and evaluation of solid dispersions of pilocarpine hydrochloride for alleviation of xerostomia].
Oda M; Sato M; Yagi N; Ohno K; Miyazaki S; Watanabe S; Takada M
Yakugaku Zasshi; 1997 Jan; 117(1):59-64. PubMed ID: 9120802
[TBL] [Abstract][Full Text] [Related]
34. Application of curdlan to controlled drug delivery. III. Drug release from sustained release suppositories in vitro.
Kanke M; Tanabe E; Katayama H; Koda Y; Yoshitomi H
Biol Pharm Bull; 1995 Aug; 18(8):1154-8. PubMed ID: 8535416
[TBL] [Abstract][Full Text] [Related]
35. Study on slow-release of indomethacin from suppositories containing hydrogenated soybean lecithin.
Nakajima T; Takashima Y; Furuya A; Ozawa Y; Kawashima Y
Chem Pharm Bull (Tokyo); 1988 Sep; 36(9):3696-701. PubMed ID: 3240558
[No Abstract] [Full Text] [Related]
36. Solid dispersions in the development of a nimodipine floating tablet formulation and optimization by artificial neural networks and genetic programming.
Barmpalexis P; Kachrimanis K; Georgarakis E
Eur J Pharm Biopharm; 2011 Jan; 77(1):122-31. PubMed ID: 20934511
[TBL] [Abstract][Full Text] [Related]
37. The Use of 3D Printed Molds to Cast Tablets with a Designed Disintegration Profile.
Ajmal A; Meskarzadeh A; Genina N; Hirschberg C; Boetker JP; Rantanen J
AAPS PharmSciTech; 2019 Feb; 20(3):127. PubMed ID: 30809745
[TBL] [Abstract][Full Text] [Related]
38. Thermally gelling poloxamine Synperonic T908 solution as a vehicle for rectal drug delivery.
Miyazaki S; Oda M; Takada M; Attwood D
Biol Pharm Bull; 1995 Aug; 18(8):1151-3. PubMed ID: 8535415
[TBL] [Abstract][Full Text] [Related]
39. The development of a novel in vitro discriminatory dissolution method for a class I drug in a matrix tablet formulation.
Farrell C; Butler J; Stark P; Madden H; Devane J
Adv Exp Med Biol; 1997; 423():217-20. PubMed ID: 9269498
[No Abstract] [Full Text] [Related]
40. Drug release and swelling kinetics of directly compressed glipizide sustained-release matrices: establishment of level A IVIVC.
Sankalia JM; Sankalia MG; Mashru RC
J Control Release; 2008 Jul; 129(1):49-58. PubMed ID: 18456362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
